Downregulation of miR-17~92 expression increase paclitaxel sensitivity in human ovarian carcinoma SKOV3-TR30 cells via BIM instead of PTEN

International Journal of Molecular Sciences

Volumn 14, Issue 2, 2013, Pages 3802-3816

  Shuang, Ting ^a   Shi, Chunxue ^a,b   Chang, Shuang ^a   Wang, Min ^a   Bai, Cui Hong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Women and Infants Hospital of Shenyang   (China)

Author keywords

BIM; miR 17 92 cluster; Ovarian carcinoma; Paclitaxel resistance; PTEN; Transduction

Indexed keywords

BH3 PROTEIN; BIM PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MICRORNA; MICRORNA 17; MICRORNA 92; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; OVARY CARCINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 84875122941     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14023802     Document Type: Article

References (22)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60, 277-300.
2. Filipowicz, W.; Bhattacharyya, S.N.; Sonenberg, N. Mechanisms of posttranscriptional regulation by microRNAs: Are the answers in sight? Nat. Rev. Genet. 2008, 9, 102-114.
3. Caldas, C.; Brenton, J.D. Sizing up miRNAs as cancer genes. Nat. Med. 2005, 11, 712-714.
4. Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6, 857-866.
5. Esquela-Kerscher, A.; Slack, F.J. Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6, 259-269.
6. Cho, W.C. MicroRNAs: Potential biomarkers for cancer diagnosis prognosis and targets for therapy. Int. J. Biochem. Cell Biol. 2010, 42, 1273-1281.
7. William, C.S.; Cho, W.C. MicroRNAs in cancer-from research to therapy. Biochem. Biophys. Acta 2010, 1805, 209-217.
8. Kuwana, T.; Bouchier-Hayes, L.; Chipuk, J.E.; Bonzon, C.; Sullivan, B.A. Green, D.R.; Newmeyer, D.D. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell 2005, 17, 525-535.
9. Letai, A.; Bassik, M.C.; Walensky, L.D.; Sorcinelli, M.D.; Weiler, S.; Korsmeyer, S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002, 2, 183-192.
10. Ota, A.; Tagawa, H.; Karnan, S.; Tsuzuki, S.; Karpas, A.; Kira, S.; Yoshida, Y.; Seto, M. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 2004, 64, 3087-3095.
11. He, L.; Thomson, J.M.; Hemann, M.T.; Hernando-Monge, E.; Mu, D.; Goodson, S.; Powers, S.; Cordon-Cardo, C.; Lowe, S.W.; Hannon, G.J.; Hammond, S.M. A microRNA polycistron as a potential human oncogene. Nature 2005, 435, 828-833.
12. Lewis, B.P.; Shih, I.H.; Jones-Rhoades, M.W.; Bartel, D.P.; Burge, C.B. Prediction of mammalian microRNA targets. Cell 2003, 115, 787-798.
13. Willis, S.N.; Fletcher, J.I.; Kaufmann, T.; van Delft, M.F.; Chen, L.; Czabotar, P.E.; Ierino, H.; Lee, E.F.; Fairlie, W.D.; Bouillet, P.; et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007, 315, 856-859.
14. Tanaka, M.; Grossman, H.B. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth; down regulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Ther. 2003, 10, 1636-1642.
15. Wu, H.; Cao, Y.; Weng, D.; Xing, H.; Song, X.; Zhou, J.; Xu, G.; Lu, Y.; Wang, S.; Ma, D. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian carcinoma cell lines and related mechanisms. Cancer Lett. 2008, 271, 260-271.
16. Gao, X.; Zhang, R.; Qu, X. MiR-15a, miR-16-1 and miR-17~92 cluster expression are linked to poor prognosis in multiple myeloma. Leuk. Res. 2012, 36, 1505-1509.
17. Ouchida, M.; Kanzaki, H. Novel direct targets of miR-19a identified in breast cancer cells by a quantitative proteomic approach. PLoS One 2012, 7, e44095.
18. Baumhoer, D.; Zillmer, S.; Unger, K.; Rosemann, M.; Atkinson, M.J.; Irmler, M.; Beckers, J.; Siggelkow, H.; von Luettichau, I.; Jundt, G.; et al. MicroRNA profiling with correlation to gene expression revealed the oncogenic miR-17~92 cluster to be up-regulated in osteosarcoma. Cancer Genet. 2012, 205, 212-219.
19. Ohyashiki, K.; Umezu, T.; Yoshizawa, S.; Ito, Y.; Ohyashiki, M.; Kawashima, H.; Tanaka, M.; Kuroda, M.; Ohyashiki, J.H. Clinical impact of down-regulated plasma miR-92a levels in non-hodgkin's lymphoma. PLoS One 2011, 6, e16408.
20. Grimson, A.; Farh, K.K.; Johnston, W.K.; Garrett-Engele, P.; Lim, L.P.; Bartel, D.P. MicroRNA targeting specificity in mammals: Determinants beyond seed pairing. Mol. Cell. 2007, 27, 91-105.
21. Xiao, C.; Srinivasan, L.; Calado, D. P; Patterson, H.C.; Zhang, B.; Wang, J.; Henderson, J.M.; Kutok, J.L.; Rajewsky, K. Lymphoproliferative disease and autoimmunity in mice with increased miR-17~92 expression in lymphocytes. Nat. Immunol. 2008, 9, 405-414.
22. Wang, J.; Zhou, J.Y.; Wu, G.S. Bim protein degradation contributes to cisplatin resistance. J. Biol. Chem. 2011, 286, 22384-22392.